Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
JPMA to Discuss Ways to Promote DX in Commercial Production in FY2025
The Japan Pharmaceutical Manufacturers Association (JPMA) will discuss measures to efficiently use AI in the field of quality control in FY2025 including ways to fuel digital transformation (DX) in commercial production. The initiative forms part of a FY2025 action plan…
To read the full story
Related Article
ORGANIZATION
- JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
April 16, 2026
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…